EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

Annals of the Rheumatic Diseases

Volumn 65, Issue 10, 2006, Pages 1312-1324

  Zhang, W ^a   Doherty, M ^a   Bardin, T ^b   Pascual, E ^c   Barskova, V ^d   Conaghan, P ^e   Gerster, J ^f   Jacobs, J ^g   Leeb, B ^h   Liote F ^c   McCarthy, G ⁱ   Netter, P ^j   Nuki, G ^k   Perez Ruiz, F ^l   Pignone, A ^m   Pimentao J ⁿ   Punzi, L ^o   Roddy, E ^a   Uhlig, T ^p   Zimmermann Gorska I ^q  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^c HÔPITAL LARIBOISIÈRE   (France)

^d V A NASONOVA RESEARCH INSTITUTE OF RHEUMATOLOGY   (Russian Federation)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f NESTLÉ RESEARCH CENTER   (Switzerland)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h Lower Austrian Center for Rheumatology   (Austria)

ⁱ MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^j UNIVERSITÉ DE LORRAINE   (France)

^k UNIVERSITY OF EDINBURGH   (United Kingdom)

^l HOSPITAL DE CRUCES   (Spain)

^m UNIVERSITY OF FLORENCE   (Italy)

ⁿ HOSPITAL EGAS MONIZ   (Portugal)

^o UNIVERSITY OF PADOVA   (Italy)

^p DIAKONHJEMMET HOSPITAL   (Norway)

^q POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALLOPURINOL; AZAPROPAZONE; BENZBROMARONE; COLCHICINE; CORTICOSTEROID; CORTICOTROPIN; CYCLOOXYGENASE 2 INHIBITOR; DIURETIC AGENT; ETORICOXIB; FEBUXOSTAT; FENOFIBRATE; HERBACEOUS AGENT; ICE; LOSARTAN; NONSTEROID ANTIINFLAMMATORY AGENT; OXIPURINOL; PLACEBO; PREDNISONE; PROBENECID; PURINE; ROFECOXIB; STEROID; SULFINPYRAZONE; TISOPURINE; TRIAMCINOLONE ACETONIDE; URATE; URIC ACID; URICOSURIC AGENT; XANTHINE OXIDASE INHIBITOR;

ABDOMINAL PAIN; ALCOHOL CONSUMPTION; ARTHROPATHY; ARTICLE; ASPIRATION; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CATARACT; CLINICAL TRIAL; COMORBIDITY; CONSENSUS DEVELOPMENT; COST EFFECTIVENESS ANALYSIS; DESENSITIZATION; DESQUAMATION; DIARRHEA; DIET; DIZZINESS; DOSE RESPONSE; DRUG COST; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG WITHDRAWAL; DUODENUM ULCER; DYSPEPSIA; EOSINOPHILIA; ERYTHEMA; EVIDENCE BASED PRACTICE; FEVER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; GOUT; HEADACHE; HEPATITIS; HUMAN; HYPERSENSITIVITY; JOINT ASPIRATION; KIDNEY FAILURE; LIVER TOXICITY; NAUSEA; OBESITY; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RADIOGRAPHY; RASH; RECURRENT DISEASE; RISK FACTOR; VASCULITIS; VOMITING; WEIGHT REDUCTION;

ACUTE DISEASE; DELPHI TECHNIQUE; EVIDENCE-BASED MEDICINE; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; LIFE STYLE; RISK FACTORS; TREATMENT OUTCOME;

EID: 33748608331     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.055269     Document Type: Article

References (116)

1. Neogi T, Hunter DJ, Chasson CE, Cunningham JA, Zhang YQ. Frequency of Inappropriate management of acute gout attacks. J Rheumatol 2006;33:104-9.
2. Mikuls TR, Curtis J, Allison J, Hicks RW, Saag KG. Medication errors with the use of gout related therapies: results from the United States Pharmacopeia MEDMARXsm Surveillance System. Arthritis Rheum 2004;50(9 suppl):S339-40.
3. Zhang W, Doherty M, Pascual-Gomez E, Bardin T, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Ann Rheum Dis 2006;65:1301-11.
4. Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005;64:669-81.
5. Cohen J. Statistical power analysis for the behavioral sciences, 2nd edition. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988.
6. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310:452-4.
7. Altman DG. Confidence intervals for the number needed to treat. BMJ 1998;317:1309-12.
8. Kleinbaum DG, Kuppler LL, Morgenstern H. Epidemiologic research - principles and quantitative methods. New York: John Wiley and Sons, 1982.
9. Whitehead A, Whitehead J. A general parametric approach to the metaanalysis of randomized clinical trials. Stat Med 1991;10:1665-77.
10. McCarthy GM, Barthelemy CR, Veum JA, Wortmann RL. Influence of antihyperuricemic therapy on the clinical and radiographic progression of gout. Arthritis Rheum 1991;34:1489-94.
11. Rundles RW, Metz EN, Silberman HR. Allopurinol in the treatment of gout. Ann Intern Med 1966;64:229-58.
12. Yu TF. The effect of allopurinol in primary and secondary gout. Arthritis Rheum 1965;8:905-6.
13. Rosenfeld JB. Effect of long-term allopurinol administration on serial GFR in normotensive and hypertensive hyperuricemic subjects. Adv Exp Med Biol 1974;41:581-96.
14. Perez-Ruiz F, Calabozo M, Jose Fernandez-Lopez M, Herrero-Beites A, Ruiz-Lucea E, Garcia-Erauskin G, et al. Treatment of chronic gout in patients with renal function impairment: An open, randomized, actively controlled study. J Clin Rheumatol 1999;5:49-55.
15. Dessein PH, Shipton EA, Stanwix AE, Joffe BI, Ramokgadi J. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis 2000;59:539-43.
16. Kullich W, Ulreich A, Klein G. Changes in uric acid and blood lipids in patients with asymptomatic hyperuricemia treated with diet therapy in a rehabilitation procedure [in German]. Rehabilitation 1989;28:134-7.
17. Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M. Does colchicine work? The results of the first controlled study in acute gout. Aust NZ J Med 1987;17:301-4.
18. Schlesinger N, Detry MA, Holland BK, Baker DG, Beutler AM, Rull M, et al. Local ice therapy during bouts of acute gouty arthritis. J Rheumatol 2002;29:331-4.
19. Caraco Y, Putterman C, Rahamimov R, Ben Chetrit E. Acute colchicine intoxication - possible role of erythromycin administration. J Rheumatol 1992;19:494-6.
20. Minetti EE, Minetti L. Multiple organ failure in a kidney transplant patient receiving both colchicine and cyclosporine. J Nephrol 2003;16:421-5.
21. Garcia de la Torre, I. A comparative, double-blind, parallel study with tenoxicam vs placebo in acute gouty arthritis [in Spanish]. Investigacion Medico Internacional 1987;14:92-7.
22. Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004;31:2429-32.
23. Paulus HE, Schlosstein LH, Godfrey RG, Klinenberg JR, Bluestone R. Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients. Arthritis Rheum 1974;17:609-14.
24. Templeton JS. Azapropazone or allopurinol in the treatment of chronic gout and/or hyperuricaemia. A preliminary report. Br J Clin Pract 1982;36:353-8.
25. Gibson T, Simmonds HA, Potter C, Rogers V. A controlled study of the effect of long term allopurinol treatment on renal function in gout. Adv Exp Med Biol 1980;122A:257-62.
26. Bastow MD, Durrington PN, Ishola M. Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial. Metab Clin Exp 1988;37:217-20.
27. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004;363:1277-81.
28. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, daily and protein intake, and the risk of gout in men. N Engl J Med 2004;350:1093-103.
29. Frank O. Observations concerning the incidence of disturbance of lipid and carbohydrate metabolism in gout. Adv Exp Med Biol 1974;41:495-8.
30. Jacobelli S, Arteaga A, Bidegain F. Cholesterol distribution among lipoprotein fractions in patients with gout and normal controls. J Rheumatol 1986;13:774-7.
31. Takahashi S, Yamamoto T, Moriwaki Y, Tsutsumi Z, Higashino K. Increased concentrations of serum Lp(a) lipoprotein in patients with primary gout. Ann Rheum Dis 1995;54:90-3.
32. Lin K-C, Tsao H-M, Chen C-H, Chou P. Hypertension was the major risk factor leading to development of cardiovascular diseases among men with hyperuricemia. J Rheumatol 2004;31:1152-8.
33. Rapado A. Relationship between gout and arterial hypertension. Adv Exp Med Biol 1974;41:451-9.
34. Grodzicki T, Palmer A, Bulpitt Q. Incidence of diabetes and gout in hypertensive patients during 8 years of follow-up. J Hum Hypertens 1997;11:583-5.
35. Tuomilehto J, Zimmet P, Wolf E, Taylor R, Ram P, King H. Plasma uric acid level and its association with diabetes mellitus and some biologic parameters in a biracial population of Fiji. Am J Epidemiol 1988;127:321-36.
36. Lyu LC, Hsu CY, Yeh CY, Lee MS, Huang SH, Chen CL. A case-control study of the association of diet and obesity with gout in Taiwan. Am J Clin Nutr 2003;78:690-701.
37. Wetzels JJL, Kremers SPJ, Vitoria PD, De Vries H. The alcohol-tobacco relationship: a prospective study among adolescents in six European countries. Addiction 2003;98:1755-63.
38. Feher MD, Hepburn AL, Hogarth MB, Ball SG, Kaye SA. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology 2003;42:321-5.
39. Liberopoulos E, Christides D, Elisaf M. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout. J Hypertens 2002;20:347.
40. Puig JG, Mateos F, Buno A, Ortega R, Rodriguez F, Dal Re R. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. J Hypertens 1999;17:1033-9.
41. Takahashi S, Moriwaki Y, Tsutsumi Z, Yamamoto T, Hada T. Effect of a combination therapy with losartan and anti-hyperuricemic agents on uric acid metabolism in gout patients with hypertension. J Rheumatol 2001;28:M37.
42. Takahashi S, Moriwaki Y, Yamamoto T, Tsutsumi Z, Ka T, Fukuchi M. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis 2003;62:572-5.
43. Wurzner G, Gerster JC, Chiolero A, Maillard M, Fallab-Stubi CL, Brunner HR, et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2001;19:1855-60.
44. Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001;60:981-3.
45. Garbe E, Suissa S, LeLorier J. Exposure to allopurinol and the risk of cataract extraction in elderly patients. Arch Ophthalmol 1998;116:1652-6.
46. Bonnel RA, Villalba ML, Karwoski CB, Beitz J. Deaths associated with inappropriate intravenous colchicine administration. J Emerg Med 2002;22:385-7.
47. Evans TI, Wheeler MT, Small RE, Breitbach SA, Sanders KM, Roberts WN. A comprehensive investigation of inpatient intravenous colchicine use shows more education is needed. J Rheumatol 1996;23:143-8.
48. Altman RD, Honig S, Levin JM, Lightfoot RW. Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. J Rheumatol 1988;15:1422-6.
49. Daymond TJ, Laws D, Templeton JS. A comparison of azapropazone and allopurinol in the treatment of chronic gout. Br J Clin Pharmacol 1983;15:157.
50. Douglas G, Thompson M. A comparison of phenylbutazone and flufenamic acid in the treatment of acute gout. Ann Phys Med 1970;10:275-80.
51. Eberl R, Dunky A. Meclofenamate sodium in the treatment of acute gout. Results of a double-blind study. Arzneimittel-Forschung 1983;33:641-3.
52. Fraser RC, Davis RH, Walker FS. Comparative trial of azapropazone and indomethacin plus allopurinol in acute gout and hyperuricaemia. J R Coll Gen Pract 1987;37:409-11.
53. Klumb EM, Pinheiro GRC, Ferrari A, Albuquerque EMN. The treatment of acute gout arthritis. Double-blind randomized comparative study between nimesulid and indomethacin. Rev Brasil Med 1996;53:540-6.
54. Lederman R. A double-blind comparison of Etodolac (Lodine (R)) and high doses of naproxen in the treatment of acute gout. Adv Ther 1990;7:344-54.
55. Lomen PL, Turner LF, Lamborn KR, Winblad MA, Sack RL, Brinn EL. Flurbiprofen in the treatment of acute gout. A comparison with indomethacin. Am J Med 1986;80:134-9.
56. Maccagno A, Di Giorgio E, Romanowicz A. Effectiveness of etodolac ("Lodine") compared with naproxen in patients with acute gout. Curr Med Res Opin 1991;12:423-9.
57. Reardon JA, Stockman A, Darlington LG, Scott JT. Double-blind trial of feprazone and phenylbutazone in acute gout. Curr Med Res Opin 1980;6:445-8.
58. Ruotsi A, Vainio U. Treatment of acute gouty arthritis with proquazone and indomethacin. A comparative, double-blind trial. Scand J Rheumatol Suppl 1978;21:15-17.
59. Shrestha M, Morgan DL, Moreden JM, Singh R, Nelson M, Hayes JE. Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. Ann Emerg Med 1995;26:682-6.
60. Siegmeth W, Placheta P. Double-blind trial: ketoprofen versus phenylbutazone in acute gouty arthritis (author's translation) [in German]. Wiener Klinische Wochenschrift 1976;88:535-7.
61. Sturge RA, Scott JT, Hamilton EB, Liyanage SP, Dixon ST, Engler C. Multicentre trial of naproxen and phenylbutazone in acute gout. Adv Exp Med Biol 1977;76B:290-6.
62. Tumrasvin T, Deesomchok U. Piroxicam in treatment of acute gout high dose versus low dose. J Med Assoc Thailand 1985;68:111-16.
63. Tweddell ED, Willcocks WA. An evaluation of piroxicam, a new non-steroidal anti-inflammatory agent. A multicentre trial. S Afr Med J 1981;59:915-16.
64. Weiner GI, White SR, Weitzner RI, Rubinstein HM. Double-blind study of fenoprofen versus phenylbutazone in acute gouty arthritis. Arthritis Rheum 1979;22:425-6.
65. Cheng TT, Lai HM, Chiu CK, Chem YC. A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis. Clin Ther 2004;26:399-406.
66. Rubin BR, Burton R, Navarra S, Antigua J, Londono J, Pryhuber KG, et al. Efficacy and safety profile of treatment with eforicoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum 2004;50:598-606.
67. Schumacher HR, Boice JA, Daikh DI, Mukhopadhyay S, Malmstrom K, Ng J, et al. Randomised double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. BMJ 2002;324:1488-92.
68. Solomon SD, McMurray JJV, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
69. Bresalier RS, Sandier RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
70. Morris I, Varughese G, Mattingly P. Lesson of the week - colchicine in acute gout. BMJ 2003;327:1275-6.
71. Fernandez C, Noguera R, Gonzalez JA, Pascual E. Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. J Rheumatol 1999;26:2285-6.
72. Alloway JA, Moriarty MJ, Hoogland YT, Nashel DJ. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol 1920;20:111-13.
73. Groff GD, Franck WA, Raddatz DA. Systemic steroid therapy for acute gout: a clinical trial and review of the literature [review] [40 refs]. Semin Arthritis Rheum 1990;19:329-36.
74. Siegel LB, Alloway JA, Nashel DJ. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol 1994;21:1325-7.
75. Taylor CT, Brooks NC, Kelley KW. Corticotropin for acute management of gout. Ann Pharmacother 2001;35:365-8.
76. Werlen D, Gabay C, Vischer TL. Corticosteroid therapy for the treatment of acute attacks of crystal-induced arthritis: an effective alternative to nonsteroidal antiinflammatory drugs [see comment]. Rev Rhum (English edition) 1996;63:248-54.
77. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002;47:355-60.
78. Li-Yu J, Clayburne G, Sieck M, Beutler AM, Rull M, Eisner E, et al. Treatment of chronic gout, can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001;28:577-80.
79. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47-56.
80. Ferraz MB, O'Brien B. A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. J Rheumatol 1995;22:908-14.
81. Becker MA, Kisicki J, Khosravan R, Wu J, Mulford D, Hunt B, et al. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids 2004;23:1111-16.
82. Becker MA, Schumacher H, Wortmann RL, Joseph-Ridge N, Lademacher C. A safety and efficacy clinical trial of a novel nun-purine selective inhibitor of xanthine oxidase, febuxostat in subjects with gout. Ann Rheum Dis 2004;63:60.
83. Becker MA, Schumacher HR, Wortmann RL, MacDonald PA, Palo WA, Eustace D, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 2005;52:916-23.
84. Joseph-Ridge N. Phase II, dose-response, safety and efficacy clinical trial of a new oral xanthine oxidase inhibitor TMX-67 (febuxostat) in subjects with gout. Arthritis Rheum 2002;46:S142.
85. Kamatani N, Fujimori S, Hada T, Hosoya T, Kato R, Matsuzawa Y, et al. Phase II dose-response clinical trial using febuxostat (TMX-67), a novel-type xanthine oxidase/xanthine dehydrogenase inhibitor, for gout and hyperuricemia. Arthritis Rheum 2003;48:S530.
86. Kamatani N, Fujimori S, Hada T, Hosoya T, Matsuzawa Y, Ueda T, et al. Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, in an allopurinol-controlled phase III clinical trial in Japanese subjects with gout or hyperuricemia. Arthritis Rheum 2004;50:S336-7.
87. Kamatani N, Fujimori S, Hada T, Hosoya T, Matsuzawa Y, Ueda J, et al. Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase, in a phase III placebo-controlled double-blind clinical trial in Japanese subjects with gout or hyperuricemia. Arthritis Rheum 2004;50:S337.
88. WalterSack I, deVries JX, Ernst B, Frei M, Kolb S, Kosmowski J, et al. Uric acid lowering effect of oxipurinol sodium in hyperuricemic patients - therapeutic equivalence to allopurinol. J Rheumatol 1996;23:498-501.
89. Lockard O, Harmon C, Nolph K, Irvin W. Allergic reaction to allopurinol with cross-reactivity to oxypurinol. Ann Intern Med 1976;85:333-5.
90. O'Duffy J. Oxypurinol therapy in allopurinol-sensitive patients [abstract]. Arthritis Rheum 1993;36(suppl 9):S159.
91. Fam AG, Lewtas J, Stein J, Paton TW. Desensitization to allopurinol in patients with gout and cutaneous reactions. Am J Med 1992;93:299-302.
92. Fam AG, Dunne SM, Iazzetta J, Paton TW. Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum 2001;44:231-8.
93. Monev SD. How should hyperuricemia be treated in a patient with allopurinol hypersensitivity? Cleveland Clin J Med 2001;68:597-8.
94. Walz-LeBlanc BAE, Reynolds WJ, MacFadden DK. Allopurinol sensitivity in a patient with chronic tophaceous gout: success of intravenous desensitization after failure of oral desensitization. Arthritis Rheum 1991;34:1329-31.
95. Scott JT. Comparison of allopurinol and probenecid. Ann Rheum Dis 1966;25:623-6.
96. Bartels EC, Matossian GS. Gout: six-year follow-up on probenecid (benemid) therapy. Arthritis Rheum 1959;2:193-202.
97. Jansen TLT, Reinders MK, Van Roon EN, Brouwers JRBJ. Benzbromarone withdrawn from the European market: another case of "absence of evidence is evidence of absence"? Clin Exp Rheumatol 2004;22:651.
98. Marukawa Y, Oishi N, Mizukoshi E, Tsuji H, Yamashita T, Kaji K, et al. A case of subacute hepatic failure associated with benzbromarone [in Japanese]. Acta Hepatol Jpn 2004;24:354-9.
99. Arai M, Yokosuka O, Fujiwara K, Kojima H, Kanda T, Hirasawa H, et al. Fulminant hepatic failure associated with benzbromarone treatment: a case report. J Gastroenterol Hepatol 2002;17:625-6.
100. Wagayama H, Shiraki K, Sugimoto K, Fujikawa K, Shimizu A, Takase K, et al. Fatal fulminant hepatic failure associated with benzbromarone. J Hepatol 2000;32:874.
101. Van Der Klauw MM, Houtman PM, Stricker BHC, Spoelstra P. Hepatic injury caused by benzbromarone. J Hepatol 1994;20:376-9.
102. Yamanaka H, Togashi R, Hakoda M, Terai C, Kashiwazaki S, Dan T, et al. Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. Adv Exp Med Biol 1998;431:13-18.
103. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR, Saag KG. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 2005;64:267-72.
104. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis. Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145-55.
105. Pendleton A, Arden N, Dougados M, Doherty M, Bannwarth B, Bijlsma JW, et at. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2000;59:936-44.
106. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis J, Dijkmans B, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:442-52.
107. Prodigy Guidance - Gout. http:www prodigy nhs uk/guideline asp?gt=Gout 2004; accessed 09-05-, 2005.
108. Meyers OL, Cassim B, Mady GM. Hyperuricaemia and gout: clinical guidelines. S Afr Med J 2003;93:961-71.
109. Nakajima H, Matsuzawa Y. Introduction of the new guideline for the management of hyperuricemia and gout with special reference to its policy. Jpn J Clin Med 2003;61(suppl 1):442-9.
110. Roemjinders H, Gorter KJ. Dutch general practitioners gout guidelines. Ned Tijd Genees 2002;146:309-13.
111. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines [review]. BMJ 1999;318:593-6.
112. Canadian Task Force on the Periodic Health Examination The periodic health examination. Can Med Assoc J 1979;121:1193-254.
113. Roddy E, Zhang W, Doherty M, Arden NK, Barlow J, Birrell F, et al. Evidence-based recommendations for the role of exercise in the management of osteoarthritis of the hip or knee - the MOVE consensus. Rheumatology (Oxford) 2005;44:67-73.
114. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet 1999;354:1896-900.
115. Moher D, Schulz KF, Altman D, Lepage L. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285:1987-91.
116. Hynes RB, Sacket DL, Gray JMA, Cook DJ, Guyatt GH. Transferring evidence from research into practice. 1. The role of clinical care research evidence in clinical decisions. Evidence Based Medicine 1996;1:196-7.